Business Context and Reporting Period
Company: Arrowhead Research Corporation (formerly InterActive Group, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2009
Business Model: Development-stage nanotechnology holding company focused on electronics and biotech. The Company forms, acquires, and operates subsidiaries to commercialize nanotechnologies. It currently holds majority stakes in Unidym, Inc. (carbon nanotubes for electronics) and Calando Pharmaceuticals, Inc. (RNAi therapeutics), along with wholly-owned non-operating subsidiaries and minority investments in Nanotope and Leonardo Biosystems.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 |
|---|---|---|
| Revenue | $3,773,147 | $1,303,201 |
| Net Loss | $(19,308,392) | $(27,089,030) |
| Operating Expenses | $23,501,783 | $36,305,782 |
| Cash and Cash Equivalents (End of Period) | $2,020,224 | $10,093,585 |
| Total Assets | $7,702,174 | $17,255,442 |
| Stockholders' Equity | $4,857,936 | $12,302,609 |
| Debt Obligations | $726,534 (Capital Lease) | $1,536,990 (Capital Lease + Notes) |
Note: The Company does not report gross margins or net margins as it is a development-stage entity with no significant cost of goods sold structure for its primary R&D activities.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 189% to $3.77 million, driven primarily by a $1.75 million license fee and $678,000 inventory sale from Calando's licensing of its IT-101 platform to Cerulean Pharma.
- Loss Reduction: Net loss decreased by approximately $7.8 million (29%) due to significant cost-cutting measures, including facility closures (New York office, Unidym Texas facility, Calando lab) and staff reductions.
- Cash Burn: Cash reserves declined by $8.1 million to $2.0 million. The Company raised $7.3 million in capital and $4.4 million from asset sales/licensing during the year.
- Strategic Shift: Subsidiaries shifted from internal development to a licensing/partnership model to conserve cash. Unidym transferred CNT production assets to a third party (CCNI) to reduce capital intensity.
Guidance, Outlook, and Risks
Liquidity and Outlook: Management projects sufficient cash to fund operations through September 30, 2010, based on a December 2009 private placement expected to raise approximately $3.2 million. The Company is actively pursuing out-licensing, subsidiary sales, and joint development partnerships to generate revenue.
Material Risks:
- NASDAQ Compliance: The Company received a deficiency notice for failing to maintain the $1.00 minimum bid price (trading at ~$0.51). It has a 180-day grace period to regain compliance or face delisting. A reverse stock split was authorized by shareholders.
- Intellectual Property: Unidym's critical license from Rice University contains an insolvency provision; failure to meet financial covenants could result in termination of rights.
- Capital Needs: As a development-stage company, the entity requires significant additional capital to complete clinical trials (Calando) and product commercialization (Unidym). Failure to secure funding could force further operational curtailment.
Investor Verification Checklist
- Cash Runway: Verify the closing of the December 2009 private placement ($3.2M) and confirm if the $2.0M cash balance is sufficient to meet the September 2010 liquidity target.
- NASDAQ Status: Monitor stock price to ensure compliance with the $1.00 minimum bid requirement by March 15, 2010, or confirm execution of a reverse stock split.
- Calando Milestones: Track the progress of the CALAA-01 Phase I clinical trial and the potential for future milestone payments from Cerulean Pharma.
- Unidym Licensing: Assess the status of the Rice University license agreement and the commercialization progress of transparent conductive films with manufacturing partners.
- Related Party Transactions: Review the terms of investments in Nanotope and Leonardo, where the CEO holds significant personal interests and serves as CEO.